{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:17:54Z","timestamp":1792977474339,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2944,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Approximately half of the patients presenting with new-onset heart failure (HF) have HF with preserved left ventricular ejection fraction (HFpEF) and HF with mid-range left ventricular ejection fraction (HFmrEF). These patients have neurohormonal activation like that of HF with reduced ejection fraction; however, beta-blockers and angiotensin-converting enzyme inhibitors have not been shown to improve their outcomes, and current treatment for these patients is symptom based and empiric. Sympathoinhibition using parasympathetic stimulation has been shown to improve central and peripheral aspects of the cardiac nervous system, reflex control, induce myocyte cardioprotection, and can lead to regression of left ventricular hypertrophy. Beneficial effects of autonomic regulation therapy (ART) using vagus nerve stimulation (VNS) have also been observed in several animal models of HFpEF, suggesting a potential role for ART in patients with this disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Patients with Heart Failure and Preserved Ejection Fraction (ANTHEM-HFpEF) study is designed to evaluate the feasibility, tolerability, and safety of ART using right cervical VNS in patients with chronic, stable HFpEF and HFmrEF. Patients with symptomatic HF and HFpEF or HFmrEF fulfilling the enrolment criteria will receive chronic ART with a subcutaneous VNS system attached to the right cervical vagus nerve. Safety parameters will be continuously monitored, and cardiac function and HF symptoms will be assessed every 3 months during a post-titration follow-up period of at least 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ANTHEM-HFpEF study is likely to provide valuable information intended to expand our understanding of the potential role of ART in patients with chronic symptomatic HFpEF and HFmrEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12241","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T05:34:43Z","timestamp":1514439283000},"page":"95-100","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Autonomic Regulation Therapy to Enhance Myocardial Function in Heart Failure Patients: The ANTHEM-HFpEF Study"],"prefix":"10.1093","volume":"5","author":[{"given":"Lorenzo A.","family":"DiCarlo","sequence":"first","affiliation":[{"name":"LivaNova PLC , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Libbus","sequence":"additional","affiliation":[{"name":"LivaNova PLC , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Uday","family":"Kumar","sequence":"additional","affiliation":[{"name":"Yashoda Hospital , Secunderabad ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mittal","sequence":"additional","affiliation":[{"name":"Medanta\u2014The Medicity , New Delhi ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra K.","family":"Premchand","sequence":"additional","affiliation":[{"name":"Krishna Institute of Medical Science , Secunderabad ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badri","family":"Amurthur","sequence":"additional","affiliation":[{"name":"LivaNova PLC , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce H.","family":"KenKnight","sequence":"additional","affiliation":[{"name":"LivaNova PLC , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Ardell","sequence":"additional","affiliation":[{"name":"University of California\u2014Los Angeles , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder S.","family":"Anand","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, University of Minnesota , Cardiology 111 C, One Veterans Drive, Minneapolis, MN, 55417 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"key":"2026012115120574000_ehf212241-bib-0001","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":"2009 focused update: ACCF\/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation"},{"key":"2026012115120574000_ehf212241-bib-0002","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4065\/mcp.2010.0841","article-title":"Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?","volume":"86","author":"Oghlakian","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2026012115120574000_ehf212241-bib-0003","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2010.04.004","article-title":"HFSA 2010 comprehensive heart failure practice guideline","volume":"16","author":"Lindenfeld","year":"2010","journal-title":"J Card Fail"},{"key":"2026012115120574000_ehf212241-bib-0004","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cardfail.2007.04.006","article-title":"Systolic and diastolic heart failure: differences and similarities","volume":"13","author":"Chatterjee","year":"2007","journal-title":"J Card Fail"},{"key":"2026012115120574000_ehf212241-bib-0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"New Engl J Med"},{"key":"2026012115120574000_ehf212241-bib-0006","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012115120574000_ehf212241-bib-0007","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1161\/CIRCRESAHA.114.302589","article-title":"The autonomic nervous system and heart failure","volume":"114","author":"Florea","year":"2014","journal-title":"Circ Res"},{"key":"2026012115120574000_ehf212241-bib-0008","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur Heart J"},{"key":"2026012115120574000_ehf212241-bib-0009","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026012115120574000_ehf212241-bib-0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115120574000_ehf212241-bib-0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026012115120574000_ehf212241-bib-0012","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026012115120574000_ehf212241-bib-0013","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115120574000_ehf212241-bib-0014","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1113\/JP271869","article-title":"Translational neurocardiology: preclinical models and cardioneural integrative aspects","volume":"594","author":"Ardell","year":"2016","journal-title":"J Physiol"},{"key":"2026012115120574000_ehf212241-bib-0015","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/CIRCULATIONAHA.107.760405","article-title":"Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy","volume":"118","author":"Olshansky","year":"2008","journal-title":"Circulation"},{"key":"2026012115120574000_ehf212241-bib-0016","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1113\/jphysiol.2012.241943","article-title":"Acute vagal stimulation attenuates cardiac metabolic response to beta-adrenergic stress","volume":"590","author":"Vimercati","year":"2012","journal-title":"J Physiol"},{"key":"2026012115120574000_ehf212241-bib-0017","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1172\/JCI39778","article-title":"Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents","volume":"120","author":"Kanazawa","year":"2010","journal-title":"J Clin Invest"},{"key":"2026012115120574000_ehf212241-bib-0018","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(14)60872-X","article-title":"Chronic autonomic regulation therapy mitigates adverse remodeling induced by pressure overload in the guinea pig heart","volume":"63","author":"Beaumont","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012115120574000_ehf212241-bib-0019","article-title":"Vagus nerve stimulation normalizes autonomic neural processing and reduces cardiac hypertrophy in a canine model of preserved ejection fraction heart failure","volume":"134","author":"Ardell","year":"2016","journal-title":"Circulation"},{"key":"2026012115120574000_ehf212241-bib-0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/eurheartj\/ehu345","article-title":"Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the Neural Cardiac Therapy for Heart Failure (NECTAR-HF) randomized controlled trial","volume":"36","author":"Zannad","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115120574000_ehf212241-bib-0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jacc.2016.03.525","article-title":"Vagus nerve stimulation for the treatment of heart failure: the INOVATE-HF trial","volume":"68","author":"Gold","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012115120574000_ehf212241-bib-0022","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.cardfail.2014.08.009","article-title":"Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial","volume":"20","author":"Premchand","year":"2014","journal-title":"J Card Fail"},{"key":"2026012115120574000_ehf212241-bib-0023","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cardfail.2015.11.002","article-title":"Extended follow-up of patients with heart failure receiving autonomic regulation therapy in the ANTHEM-HF study","volume":"22","author":"Premchand","year":"2016","journal-title":"J Card Fail"},{"key":"2026012115120574000_ehf212241-bib-0024","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1161\/01.RES.69.5.1389","article-title":"Single cardiac vagal fiber activity, acute myocardial ischemia, and risk for sudden death","volume":"69","author":"Cerati","year":"1991","journal-title":"Circ Res"},{"key":"2026012115120574000_ehf212241-bib-0025","doi-asserted-by":"crossref","first-page":"R950","DOI":"10.1152\/ajpregu.00223.2012","article-title":"Remodeling of intrinsic cardiac neurons: effects of beta-adrenergic receptor blockade in guinea pig models of chronic heart disease","volume":"303","author":"Hardwick","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2026012115120574000_ehf212241-bib-0026","volume-title":"Cyberonics announces CE Mark approval of the VITARIA system for treatment of chronic heart failure","author":"PRNewswire","year":"2015"},{"key":"2026012115120574000_ehf212241-bib-0027","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cardfail.2013.07.002","article-title":"Autonomic regulation therapy for the improvement of left ventricular function and heart failure symptoms: the ANTHEM-HF study","volume":"19","author":"Dicarlo","year":"2013","journal-title":"J Card Fail"},{"key":"2026012115120574000_ehf212241-bib-0028","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00557.2015","article-title":"Central\u2013peripheral neural network interactions evoked by vagus nerve stimulation: functional consequences on control of cardiac function","author":"Ardell","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012115120574000_ehf212241-bib-0029","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/CIRCRESAHA.115.302922","article-title":"Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies","volume":"115","author":"Sharma","year":"2014","journal-title":"Circ Res"},{"key":"2026012115120574000_ehf212241-bib-0030","first-page":"4626","article-title":"Chronic baroreflex activation by the Rheos system: an overview of results from European and North American feasibility studies","volume":"2009","author":"Lovett","year":"2009","journal-title":"Conf Proc IEEE Eng Med Biol Soc"},{"key":"2026012115120574000_ehf212241-bib-0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100179","article-title":"Cholinergic signaling exerts protective effects in models of sympathetic hyperactivity-induced cardiac dysfunction","volume":"9","author":"Gavioli","year":"2014","journal-title":"PLoS One"},{"key":"2026012115120574000_ehf212241-bib-0032","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/eurheartj\/ehq391","article-title":"Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure","volume":"32","author":"De Ferrari","year":"2011","journal-title":"Eur Heart J"},{"key":"2026012115120574000_ehf212241-bib-0033","volume-title":"BioControl medical cardio device gets CE Mark certification","author":"Globes","year":"2009"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/5\/1\/95\/66137683\/eschf_5_1_95.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/5\/1\/95\/66137683\/eschf_5_1_95.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:16:15Z","timestamp":1769026575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/5\/1\/95\/8403955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12,28]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12241","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,12,28]]},"assertion":[{"value":"2017-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}